Melinta Therapeutics Revenue and Competitors

Location

$877.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Melinta Therapeutics's estimated annual revenue is currently $38.8M per year.(i)
  • Melinta Therapeutics's estimated revenue per employee is $193,750
  • Melinta Therapeutics's total funding is $877.4M.

Employee Data

  • Melinta Therapeutics has 200 Employees.(i)
  • Melinta Therapeutics grew their employee count by 12% last year.

Melinta Therapeutics's People

NameTitleEmail/Phone
1
VP Market Access & TradeReveal Email/Phone
2
Head PharmacovigilanceReveal Email/Phone
3
VP, Anti-Fungal MarketingReveal Email/Phone
4
VP, Manufacturing and SupplyReveal Email/Phone
5
VP Drug DevelopmentReveal Email/Phone
6
VP, Commercial Strategy & OperationsReveal Email/Phone
7
VP Anti-Infective MarketingReveal Email/Phone
8
Head Digital MarketingReveal Email/Phone
9
VP, Medical AffairsReveal Email/Phone
10
Head Financial Planning and AnalysisReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Melinta Therapeutics?

Melinta Therapeutics, Inc. (MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.

keywords:N/A

$877.4M

Total Funding

200

Number of Employees

$38.8M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Melinta Therapeutics News

2022-04-19 - The Worldwide Genitourinary Drugs Industry is Expected to Reach ...

Abbott; Allergan; Antares Pharma; Asieris Pharmaceuticals ... Johnson & Johnson Services, Inc. Melinta Therapeutics Inc. Merck & Co., Inc.

2022-04-13 - The Chlamydia Market Is Anticipated to Grow with a Considerable CAGR In The 7MM During The Study Period (2019-32), Assesses DelveInsight

Key Chlamydia companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience,...

2022-04-06 - Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL ...

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.

2021-09-20 - Melinta Therapeutics : Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July. The Centers for Medicare & Medicaid S ...

2021-03-15 - Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

MORRISTOWN, N.J.--(BUSINESS WIRE)--Mar 15, 2021-- Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the t ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$54.1M200-5%N/A
#2
$39.6M2006%N/A
#3
$53.9M2006%N/A
#4
$67.1M200N/AN/A
#5
$46.2M200N/AN/A